RECRUITINGOBSERVATIONAL
Type 1 Diabetes Recurrence in Pancreas Transplants
Recurrence of T1D in Pancreas Transplantation
About This Trial
The hypothesis is that humoral and cellular islet-specific responses are an early risk factor for recurrence of autoimmunity and hyperglycemia in simultaneous pancreas-kidney (SPK) recipients independent of alloimmunity. This study will test the hypothesis and will assess their individual and combined predictive value.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patient has been fully informed and has signed a dated IRB approval willing to sign a consent form form and is willing to follow study procedures for the extent of the study (24 months). Parent or legal guardian must provide written consent for patients \<18 years of age.
- Age 18-75 years.
- Recipient of simultaneous pancreas and kidney transplant
- Primary or secondary renal allograft: living or deceased
Who Should NOT Join This Trial:
- Patient has previously received or is receiving an organ transplant other than a pancreas-kidney.
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patient has been fully informed and has signed a dated IRB approval informed consent form and is willing to follow study procedures for the extent of the study (24 months). Parent or legal guardian must provide written consent for patients \<18 years of age.
* Age 18-75 years.
* Recipient of simultaneous pancreas and kidney transplant
* Primary or secondary renal allograft: living or deceased
Exclusion Criteria:
* Patient has previously received or is receiving an organ transplant other than a pancreas-kidney.
Locations (1)
University of Miami Miller School of Medicine Transplant Clinic
Miami, Florida, United States